Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Support Measures Herald New Drug Rush In China?

This article was originally published in PharmAsia News

Executive Summary

Domestic developers of original drugs in China are beginning to gain clinical trial approvals (CTAs) in record times, especially for therapies to treat prevalent serious diseases such as cancers and hepatitis, helped by alliances with academia, the government push for innovation, and major CRO WuXi.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register